Speaker: Dr. Wanbo Tang; 

Title: TCR-mimic antibody discovery platform based on Biocytogen’s fully human RenMice; 

Webinar Description: 

Therapeutic antibodies play an important role in cancer immunotherapy. However, traditional antibody therapies are limited to targeting a narrow range of tumor-associated antigens located on the cell surface or in soluble form. In contrast, the human T cell receptor (TCR) recognizes its cognate peptide antigens presented on human leukocyte antigen (HLA) molecules, enabling the detection of a broader spectrum of targets, including intracellular proteins.

Biocytogen has established an innovative platform to generate fully human TCR mimic (TCRm) antibodies with enhanced specificity and affinity for their targets. These TCRm antibodies possess the same recognition function as TCRs, allowing them to effectively recognize endogenously processed peptides bound to human leukocyte antigen (pHLA) molecules. This includes intracellular tumor-associated antigens, cancer-testis antigens (CTAs), mutated protein antigens, and viral oncoproteins.

By overcoming the target limitations of traditional antibody therapies, TCRm antibodies provide a powerful and versatile tool to advance tumor immunotherapy, enabling the targeting of intracellular and otherwise inaccessible antigens.